INTRODUCTION
============

Iron proteins have key roles in normal brain function and the processes of brain development, including neurogenesis, myelination, synaptic development, and energy and neurotransmitter metabolism.[@nux015-B1] The large amount of iron required to perform these functions is acquired from blood, mainly during periods of rapid brain growth.[@nux015-B4] In adult life, iron uptake by the brain still occurs, though at levels significantly lower than those during development.[@nux015-B5] Iron levels in the brain can be altered by peripheral iron levels and iron nutrition. Effects of iron nutrition on the brain have been studied extensively in iron deficiency, the leading nutrient deficiency worldwide.[@nux015-B6] Iron deficiency during both development and adulthood results in diverse effects on neural function.[@nux015-B7] In contrast, the effects of high peripheral iron status on the brain are poorly understood. The widespread use of iron-fortified foods, such as milk replacers, other beverages, and solid foods, as well as iron supplements has decreased the prevalence of deficiency in all age groups in many populations. However, iron-augmented diets also have the potential to increase iron intake above levels needed to prevent deficiency.[@nux015-B10]

Brain aging and protein-misfolding neurodegenerative diseases such as Alzheimer disease, Parkinson disease, Huntington disease, and amyotrophic lateral sclerosis share some common mechanisms.[@nux015-B11] Older age is the greatest risk factor for the accumulation of misfolded proteins that typifies the earliest stages of Alzheimer disease and Parkinson disease.[@nux015-B12] Therefore, Alzheimer disease and Parkinson disease may represent pathologic extensions of normal processes of brain aging. Protein misfolding, protein accumulation, and neurodegeneration are also core features of Huntington disease and amyotrophic lateral sclerosis.[@nux015-B13]^,^[@nux015-B14] Accumulation of iron in the brain occurs with human aging, and iron levels correlate with cognitive function.[@nux015-B15]^,^[@nux015-B16] Iron accumulation in the brain also occurs with Alzheimer disease, Parkinson disease, Huntington disease, and amyotrophic lateral sclerosis.[@nux015-B17] Alzheimer disease, Parkinson disease, and amyotrophic lateral sclerosis most commonly manifest as sporadic diseases.[@nux015-B11] They are modeled in mice by mimicking the less-common genetic forms of the human disease and/or by using toxicants.[@nux015-B21] Huntington disease is caused by a single gene, and several genetic mouse models exist.[@nux015-B24]

There is evidence from human and animal studies that iron dysregulation is one factor that contributes to the neurodegeneration associated with Alzheimer disease, Parkinson disease, Huntington disease, and amyotrophic lateral sclerosis.[@nux015-B25] In health, iron homeostatic mechanisms maintain not only appropriate iron absorption and tissue levels but also cellular and subcellular location and molecular associations. Dysregulation of these processes results in increased production of reactive oxygen species, resulting in molecular damage, mitochondrial dysfunction, and cell death.[@nux015-B26] Despite evidence of a contributory role of iron in brain aging and neurodegeneration, the role of elevated iron intake as a modifier of these processes is poorly understood.[@nux015-B15] Given the increasing life expectancy and the resulting increased prevalence of neurodegenerative diseases,[@nux015-B11] it is particularly important to understand the effects of high iron intake at various life stages on brain aging.

Recommended Dietary Allowances for iron have been developed to prevent iron deficiency, and upper limits were established to avoid short-term adverse effects.[@nux015-B27] Possible effects of long-term iron intake above the Recommended Dietary Allowance on cognition, brain aging, and neurodegenerative processes are not understood. Furthermore, there is evidence that some populations are iron replete and have elevated iron stores.[@nux015-B28] The aim of this study was to use the methods of systematic review to investigate the effects of high iron intake or high peripheral iron status on adult cognition and outcomes of protein-misfolding neurodegenerative diseases in both animal models and humans. The findings support a role of high iron intake as a negative modifier of brain health in adults. They also highlight gaps in understanding both the mechanisms involved and the translatability of findings in animal models to humans.

METHODS
=======

Review protocol
---------------

The systematic review was undertaken in accordance with PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) guidelines.[@nux015-B29] A checklist ensuring adherence to PRISMA guidelines is shown in [Table S1](#sup1){ref-type="supplementary-material"} in the Supporting Information online. A written protocol was not used.

Information sources
-------------------

The following electronic databases were searched: MEDLINE, Scopus, CAB Abstracts, the Cochrane Central Register of Clinical Trials, and OpenGrey. A computerized literature search was conducted to identify studies that had been published up to June 28, 2016. Search strategies are shown in [Appendix S1](#sup1){ref-type="supplementary-material"} in the Supporting Information online.

Study eligibility criteria
--------------------------

Study inclusion and exclusion criteria and research questions were developed using the PICOS (population, intervention, comparators, outcome, study design) model. Included were studies investigating the effect of elevated iron intake at all postnatal life stages in mammalian models and humans on measures of adult brain health. Neurologic status in animal models is evaluated using a number of outcomes that include cognitive testing; biochemical measurement of markers linked to neurodegeneration, such as brain iron accumulation, neurotransmitter levels, and oxidative stress markers; and brain morphometry. Therefore, animal studies with diverse outcome measures were included. Human studies included were those that estimated former or current levels of iron intake or peripheral measures of iron status and their effect on brain iron, cognition, and/or the onset of neurodegenerative disease in adults. Details of the inclusion and exclusion criteria are provided in [Table 1](#nux015-T1){ref-type="table"}. Table 1PICOS criteria for inclusion and exclusion of studiesCategoryInclusion criteriaExclusion criteriaParticipantsAnimal studies: mammalsHuman studies: all races and both sexesAnimal studies: nonmammalian speciesHuman studies: hemochromatosis or neurologic disease diagnosis before determination of iron status or intake levelInterventionAnimal studies: oral administration of iron supplements or high-iron dietsHuman studies: iron supplementation or estimation of iron intake or peripheral iron status at any ageParenteral administration of ironToxic level of iron supplementation in animalsStudies of effects of maternal iron intake on progenyStudies of iron supplementation in the context of deficiencyComparatorControl group for iron intake in animal and human experimental studiesHuman studies: sex and age matched, absence of neurologic disease, lower natural iron intake or lower peripheral iron statusNoneOutcomesAnimal studies: behavior, brain biochemistry, and neuropathologyHuman studies: development of neurodegenerative disease, markers of brain iron status, cognitionAnimal and human studies: outcomes measured in preadultsStudy designExperimental animal studiesHuman studies: randomized controlled nutritional studies, all types of observational studiesEnglish languageDated up to June 2016Meta-analyses, reviews, gray literature, short communications, abstracts, and case reports

Assessment of risk of publication bias in preclinical studies
-------------------------------------------------------------

Comparing the number of studies reporting negative findings in the unpublished versus the published literature is one way to assess publication bias. Risk of publication bias was assessed by one author (S.A.). The Society for Neuroscience's online database is a collection of abstracts presented at annual meetings; the years 2007--2015 were searched. Relevant abstracts were evaluated for the presence of positive or negative findings but were not included as part of the review. Permission was obtained from the Society for Neuroscience to access this private database.

Risk of bias
------------

The quality of the included papers was assessed at the study level. For animal studies, 7 indicators of quality adapted from the National Research Council's Institute for Laboratory Animal Research were used[@nux015-B30]^,^[@nux015-B31]: (1) random allocation of treatment, (2) allocation concealment, (3) blinding, (4) stated inclusion/exclusion criteria, (5) test animal details, (6) every animal accounted for, and (7) conflict of interest statement and funding source. Human cohort and case--control studies were analyzed using tools from the Critical Appraisal Skills Program, while cross-sectional studies were assessed using tools modified from those recommended by the Agency for Healthcare Research and Quality.[@nux015-B32] The criteria were assessed independently by two reviewers (S.A. and J.H.F.); discrepancies were resolved by discussion.

Data extraction and synthesis
-----------------------------

Study characteristics and data were extracted and evaluated by two authors independently (S.A. and J.H.F.), with discrepancies resolved by discussion. Meta-analysis was not possible because of the heterogeneous nature of the studies and the varied outcomes. Papers were grouped into 4 themes: preclinical studies of the effect of high iron intake on outcomes related to behavior and brain aging ([Table 2](#nux015-T2){ref-type="table"})[@nux015-B33]; preclinical studies of the effect of high iron intake on outcomes related to neurodegenerative disease ([Table 3](#nux015-T3){ref-type="table"})[@nux015-B52]; human nutrition studies assessing the association between iron intake and brain outcomes ([Table 4](#nux015-T4){ref-type="table"})[@nux015-B67]; and human studies assessing the association between peripheral iron status and brain outcomes ([Table 5](#nux015-T5){ref-type="table"}).[@nux015-B73] Qualitative synthesis of the included studies was completed within and across the 4 themes. All findings reported in [Tables 2](#nux015-T2){ref-type="table"}, [3](#nux015-T3){ref-type="table"}, [4](#nux015-T4){ref-type="table"}, and [5](#nux015-T5){ref-type="table"} are statistically significant unless otherwise stated. Table 2Preclinical studies evaluating the effect of high iron intake on outcomes related to behavior and brain agingReferenceSex/strain/speciesIron form and dosage range[^a^](#tblfn2){ref-type="table-fn"}Age at iron supplementation and at outcome measurementBias assessment[^b^](#tblfn3){ref-type="table-fn"}Major effects of iron supplementationFredriksson et al. (1999)[@nux015-B41]Male NMRI miceFerrous succinate; 3.7--37 mg/kgIron: 10--12 dOutcome: 3 moU, U, U, U, L, U, HSupplementation produced deficits in spontaneous activity and spatial learning. Iron levels in basal ganglia were increased 22%--58%. No effect on frontal cortical ironFredriksson et al. (2000)[@nux015-B42]Male NMRI miceFerrous succinate; 7.5 mg/kgIron: 3--5 d, 10--12 d, and 19--21 dOutcome: 3 moU, U, U, U, L, U, L[^c^](#tblfn4){ref-type="table-fn"}Supplementation on days 3--5 and 10--12 resulted in (1) deficits in spontaneous activity and spatial learning and (2) a 26%--48% increase in basal ganglia ironIsacc et al. (2006)[@nux015-B43]Male C57 BL/6 miceFerrous succinate; 7.5 mg/kgIron: 10--12 dOutcome: 3--4 moU, U, U, U, L, U, L[^c^](#tblfn4){ref-type="table-fn"}Iron-supplemented mice had decreases in brain phosphatidyl choline and sphingomyelin levelsde Lima et al. (2005)[@nux015-B49]Male Wistar ratsFerrous succinate; 10 mg/kgIron: 5--7 d, 12--14 d, 19--21 d, and 30--32 dOutcome: 3 moU, U, U, U, L, U, L[^c^](#tblfn4){ref-type="table-fn"}Supplementation of iron on days 12--14 (1) impaired object recognition by ≈36% and (2) increased oxidative stress in hippocampus and substantia nigraMiwa et al. (2011)[@nux015-B51]Male Wistar ratsFerrous succinate; 10 mg/kgIron: 12--14 dOutcome: 3--24 moU, U, U, U, L, U, L[^c^](#tblfn4){ref-type="table-fn"}Supplementation increased expression of the apoptosis markers prostate apoptosis response-4 and caspase-3 protein at 3 mo but decreased expression at 24 moFernandez et al. (2011)[@nux015-B39]Male Wistar ratsFerrous succinate; 10 mg/kgIron: 12--14 dOutcome: 3--24 moU, U, U, U, L, U, L[^c^](#tblfn4){ref-type="table-fn"}Iron supplementation induced mild astrocytosis in hippocampus at 3 mo and in striatum and substantia nigra at 24 moSchroder et al. (2001)[@nux015-B46]Male Wistar ratsFerrous succinate; 2.5--30.0 mg/kgIron: 10--12 dOutcome: 3--6 moU, U, U, U, L, U, L[^c^](#tblfn4){ref-type="table-fn"}Supplementation resulted in (1) dose-dependent deficits in radial arm maze learning and (2) a 46%--92% increase in substantia nigra iron contentFigueiredo et al. (2016)[@nux015-B40]Male Wistar ratsCarbonyl iron; 10 mg/kgIron: 12--14 dOutcome: 3 moU, U, L[^d^](#tblfn5){ref-type="table-fn"}, U, L, U, LIron supplementation (1) impaired emotionally motivated behavior and recognition memory and (2) increased hippocampal protein ubiquitinationDornelles et al. (2010)[@nux015-B38]Male Wistar ratsFerrous succinate; 10 mg/kgIron: 12--14 dOutcome: 3--24 moU, U, U, U, L, U, L[^c^](#tblfn4){ref-type="table-fn"}Supplementation changed expression of mRNA encoding genes involved in iron homeostasis in an age- and brain-region-specific mannerde Lima et al. (2005)[@nux015-B35]Male Wistar ratsFerrous succinate; 10 mg/kgIron: 12--14 dOutcome: 3 moU, U, L[^d^](#tblfn5){ref-type="table-fn"}, U, L, U, L[^c^](#tblfn4){ref-type="table-fn"}Monoamine oxidase inhibition protected against behavioral effects of iron supplementationBudni et al. (2007)[@nux015-B34]Male Wistar ratsFerrous succinate; 10 mg/kgIron: 12--14 dOutcome: 3 moU, U, U, U, L, U, L[^c^](#tblfn4){ref-type="table-fn"}Monoamine oxidase inhibition decreased iron supplementation--induced oxidative stress in substantia nigra and hippocampusde Lima et al. (2008)[@nux015-B37]Male Wistar ratsFerrous succinate; 10 mg/kgIron: 12--14 dOutcome: 3 moU, U, L[^d^](#tblfn5){ref-type="table-fn"}, U, L, U, L[^c^](#tblfn4){ref-type="table-fn"}Type 4--specific phosphodiesterase inhibition protected against cognitive effects of iron supplementationde Lima et al. (2007)[@nux015-B36]Male Wistar ratsFerrous succinate; 10 mg/kgIron: 12--14 dOutcome: 3 moU, U, U, U, L, U, L[^c^](#tblfn4){ref-type="table-fn"}Iron chelation with desferoxamine protected against behavioral effects of iron supplementationRech et al. (2010)[@nux015-B45]Male Wistar ratsFerrous succinate; 10 mg/kgIron: 12--14 dOutcome: 24 moU, U, U, U, L, U, L[^c^](#tblfn4){ref-type="table-fn"}No significant effect of neonatal iron supplementation on motor activity or novel object recognitionFagherazzi et al. (2012)[@nux015-B50]Male Wistar ratsFerrous carbonyl; 10 mg/kgIron: 12--14 dOutcome: 2.5 moL, U, L[^d^](#tblfn5){ref-type="table-fn"}, U, L, U, L[^c^](#tblfn4){ref-type="table-fn"}Cannabidiol protected against deleterious effects of neonatal iron supplementationda Silva et al. (2014)[@nux015-B47]Male Wistar ratsIron carbonyl; 10 mg/kgIron: 12--14 dOutcome: 3.5 moU, U, U, U, L, U, LCannabidiol normalized cortical caspase-3, synaptophysin, and mitochondrial fission dynamin-1-like proteinPerez et al. (2010)[@nux015-B44]Male Wistar ratsFerrous succinate; 10 mg/kgIron: 12--14 dOutcome: 2--3 moU, U, U, U, L, U, L[^c^](#tblfn4){ref-type="table-fn"}Supplementation impaired long-term object recognition (≈28%) and decreased striatal acetylcholinesterase activity (≈27%)Silva et al. (2012)[@nux015-B48]Male Wistar ratsIron carbonyl; 10 mg/kgIron: 12--14 dOutcome: 2 moU, U, L[^d^](#tblfn5){ref-type="table-fn"}, U, L, U, L[^c^](#tblfn4){ref-type="table-fn"}Supplementation decreased object recognition memory (≈29%). Iron-induced changes in histone acetylation in hippocampus were rescued with butyrateLavich et al. (2015)[@nux015-B33]Male Wistar ratsIron carbonyl; 10 mg/kgIron: 12--14 dOutcome: 3 moU, U, L[^d^](#tblfn5){ref-type="table-fn"}, U, L, U, LSupplementation decreased novel object recognition (≈32%) and impaired mitochondrial dynamics. Effects of iron were rescued with the antioxidant sulforaphane[^1][^2][^3][^4][^5]Table 3Preclinical studies evaluating the effect of high iron intake on outcomes related to neurodegenerative diseaseReferenceSex/strain/species/ disease modeledIron form and dosage[^a^](#tblfn7){ref-type="table-fn"}Age(s) at supplementation and at outcome measurementBias assessment[^b^](#tblfn8){ref-type="table-fn"}Major effects of iron supplementationFredriksson et al. (2001)[@nux015-B62]Male C57BL/6 mice; PDFerrous succinate; 7.5 mg/kgIron: 10--12 dOutcome: 3--4 moU, U, U, U, L, U, L[^c^](#tblfn9){ref-type="table-fn"}Iron supplementation increased basal ganglia iron by 72%. Supplementation and adult neurotoxic MPTP treatment potentiated the depletion of basal ganglia dopamineFredriksson et al. (2003)[@nux015-B60]Male C57BL/6 mice; PDFerrous succinate; 2.5--7.5 mg/kgIron: 10--12 dOutcome: 3--4 moU, U, U, U, L, U, HIron supplementation increased basal ganglia iron up to 102%. N-methyl-D-aspartate antagonist MK801 with L-DOPA partly rescued motor effects of iron supplementationFredriksson & Archer (2003)[@nux015-B52]Male NMRI and C57BL/6 mice; PDFerrous succinate; 2.5--37 mg/kgIron: 10--12 dOutcome: 3--4 moU, U, U, U, U, U, L[^c^](#tblfn9){ref-type="table-fn"}Iron supplementation increased basal ganglia iron by 58% and decreased motor activities. MPTP potentiated effects of neonatal iron supplementationKaur et al. (2007)[@nux015-B63]Male C57BL/6 × D2 mice; PDIron carbonyl; 120 mg/kgIron: 10--17 dOutcome: 2--24 moU, U, U, U, L, U, L[^c^](#tblfn9){ref-type="table-fn"}Iron supplementation decreased striatal dopamine by up to ≈44%, decreased dopaminergic neurons in the substantia nigra by up to ≈29%, and enhanced the neurotoxic effects of MPTPPeng et al. (2007)[@nux015-B65]Male C57BL/6 mice; PDIron carbonyl; 120 mg/kgIron: 10--17 dOutcome: 2--24 moU, U, U, U, L, U, HIron supplementation decreased dopaminergic cells at 24 mo by ≈25%; the herbicide paraquat potentiated this effect; a superoxide dismutase/catalase mimetic provided some protectionArcher & Fredriksson (2007)[@nux015-B54]Male C57/BL6 mice; PDFerrous succinate; 7.5 mg/kgIron: 10--12 dOutcome: 3 moU, U, U, U, L, U, HIron supplementation increased basal ganglia iron by ≈67%. Neuroleptic agents modulated behavioral effects of ironFredriksson & Archer (2006)[@nux015-B61]Male C57/BL6 mice; PDFerrous succinate; 7.5 mg/kgIron: 10--12 dOutcome: 3 moU, U, U, U, L, U, HNeuroleptic agent haloperidol modulated the behavioral effects of iron supplementationWang et al. (2014)[@nux015-B53]Male Sprague-Dawley rats; PDIron carbonyl; 120 mg/kgIron: 10--17 dOutcome: 20 moU, U, U, U, L, U, L[^c^](#tblfn9){ref-type="table-fn"}Iron supplementation reduced motor activity and decreased striatal dopamine by ≈38%. Inhibition of sirtuin 2 provided some protectionPeng et al. (2010)[@nux015-B64]Male mutant α-synuclein mice (C57BL/ 6 strain); PDIron carbonyl; 120 mg/kgIron: 10--17 dOutcome: 12--23 moU, U, U, U, L, U, HInteraction between mutant α-synuclein and iron + paraquat combination treatment promoted loss of dopaminergic neuronsDal-Pizzol et al. (2001)[@nux015-B58]Male Wistar rats; PDFerrous succinate; 7.5--15 mg/kgIron: 10--12 dOutcome: 3 moU, U, U, U, L, U, HNeonatal iron supplementation increased substantia nigra lipid peroxidation by ≈48%--66%Chen et al. (2015)[@nux015-B57]Male/female Sprague-Dawley rats; PDIron carbonyl; 120 mg/kgIron: 10--17 dOutcome: 7--21 moU, U, U, U, L, U, LIron supplementation decreased motor activity, striatal dopamine (≈35%), and substantia nigra glutathione (≈40%) and increased nigral lipid peroxidation (≈100%)Billings et al. (2016)[@nux015-B56]Male α-synuclein transgenic mice (C57BL/6 strain); PDIron carbonyl; 120 mg/kgIron: 10--17 dOutcome: 8 moU, U, U, U, L, U, L[^c^](#tblfn9){ref-type="table-fn"}Iron supplementation promoted loss of dopaminergic neurons in wild-type mice by ≈30% but not in mutant α-synuclein transgenic miceFernandez et al. (2010)[@nux015-B59]Male AβPP/PS1 transgenic mice; ADFerrous succinate; 10 mg/kgIron: 12--14 dOutcome: 6 moU, U, U, U, U, U, LIron supplementation increased astrocytosis in the cerebral cortex of transgenic and wild-type mice. No effect of iron on amyloid plaquesBerggren et al. (2015)[@nux015-B55]Female R6/2 mice (B6/CBA stain); HDIron carbonyl; 120 mg/kg for neonates, 500 mg/kg for adultsIron: 10--17 d and 1--3 mo (in feed)Outcome: 3 moL[^d^](#tblfn10){ref-type="table-fn"}, U, L[^e^](#tblfn11){ref-type="table-fn"}, U, L, U, L[^c^](#tblfn9){ref-type="table-fn"}Neonatal iron supplementation increased the oxidative stress marker oxidized glutathione (32%--53%) and neuronal atrophy (13%--15%) in HD but not in wild-type brains. There was no effect of iron supplementation during adult lifeBerggren et al. (2016)[@nux015-B66]Female YAC128 HD mice (FVB strain); HDIron carbonyl; 120 mg/kg for neonates, 500 mg/kg for adultsIron: 10--17 d and 1--12 mo (in feed)Outcome: 12 moL[^d^](#tblfn10){ref-type="table-fn"}, U, U[^e^](#tblfn11){ref-type="table-fn"}, U, L, U, LNeonatal iron supplementation promoted striatal neuronal atrophy in HD mice (19%) but not in wild-type littermates. There was no effect of iron supplementation during adult life[^6][^7][^8][^9][^10][^11]Table 4Human nutrition studies assessing the association between iron intake and brain outcomesReferenceStudy designPopulationEvaluation of dietary iron and outcomesMain findingsAnderson et al. (1999)[@nux015-B72]Case--control103 newly diagnosed PD patients and 156 controls; WA, USAIn-person interview about diet, covering most of adult life. Risk of PDIron intake was not related to increased PD riskPowers et al. (2003)[@nux015-B71]Case--control250 newly diagnosed PD patients and 388 age- and sex-matched controls; WA, USAIn-person interview about diet, covering most of adult life. OR for risk of development of PD for each quartile of dietary factorSubjects in highest quartile of iron intake had increased risk of PD compared with those in lowest quartile (OR 1.7)Powers et al. (2009)[@nux015-B70]Case--control420 patients (median age 69 y) and 560 age-, sex-, and ethnicity-matched controls (median age, 71 y); USAIn-person interview about diet, covering most of adult life. Logistic regression used to determine OR for the development of PD for each level of dietary factorMen in highest quartile of iron intake had increased risk of PD compared with those in lowest quartile (OR 1.82)Logroscino et al. (2008)[@nux015-B69]Cohort47 406 men and 46 947 women, all health professionals; USAFFQ every 4 y of study. Outcome of PD as determined by neurologistIncreased intake of nonheme iron but not total iron is a risk for PD (relative risk = 1.27 and 1.1, respectively)Hernandez Mdel et al. (2015)[@nux015-B68]Cohort1063 healthy, older, community-dwelling men and women, mean age 73 y; UKSelf-reported food questionnaire validated in older adults. Brain iron deposits determined by MRI in brainstem, white matter, thalamus, basal ganglia, and cortex. Blood iron markers ferritin and transferrin determinedIron intake did not correlate with blood or brain iron measurements. Brain iron deposits did not correlate with blood iron measurementsHagemeier et al. (2015)[@nux015-B67]Cohort190 healthy men and women, mean age 43 y, USAHistoric (3 y) nutritional questionnaire assessing consumption of iron, calcium, vegetables, dairy, and red meat. Brain iron determined by MRI in basal ganglia, thalamus, and substantia nigraTrend toward increased brain iron with iron supplementation (*P* = 0.075). Effects were dependent on sex[^12]Table 5Human studies assessing the association between peripheral iron status and brain outcomesReferenceStudy typePopulationPeripheral iron measures and brain outcome(s)Main findingsGao et al. (2008)[@nux015-B79]Cross-sectional2000 men and women, \>65 y, rural areas; ChinaPlasma ironCognitive assessmentPlasma iron was not correlated with cognitive scoresLam et al. (2008)[@nux015-B80]Cross-sectional1451 men and women, all ambulatory, mean age 75 y; USAPlasma ironCognitive assessmentLow and high (men) or high (women) plasma iron associated with poorer performance in a battery of cognitive testsMilward et al. (2010)[@nux015-B77]Cohort800 community-dwelling adults, \>60 y; AustraliaSerum iron, transferrin saturation, and ferritin measured twice, 9 y apartCognitive assessment in year 9No relationships found between iron measures and cognitive scoresSchiepers et al. (2010)[@nux015-B78]Cohort818 adults, 50--70 y (mean age 60 y); NetherlandsTotal serum iron, total iron-binding capacity, transferrin saturation, and ferritinCognitive assessmentMeasurements taken at baseline and 3 yPeripheral iron measures were not associated with cognitive outcomesUmur et al. (2011)[@nux015-B75]Cross-sectional87 nursing home residents, \>65 y, both sexes, no neurologic diagnoses; TurkeySerum iron, transferrin saturation, and ferritinMini-mental status examinationMild CI was associated with significantly higher serum iron (98%), ferritin (58%), and transferrin saturation (107%)Mueller et al. (2012)[@nux015-B76]Case--control19 controls, 11 cases of stable mild CI, 7 cases of progressive CI, and 19 cases of early dementia; mean age ≈78 y; USASerum copper and nonheme ironCognitive testing every 6 mo for 5 yRatio of serum copper to nonheme iron increased during the progression from mild CI to Alzheimer disease. No change in nonheme ironAndreeva et al. (2013)[@nux015-B74]Cohort4959 men and women, 35--60 y; FranceHemoglobin determined in year 1; serum ferritin determined in years 1 and 6Cognitive outcomes evaluated at year 13Lower serum ferritin was associated with better outcomes of some cognitive measures in pre- and perimenopausal womenBlasco et al. (2014)[@nux015-B73]Cross-sectional23 obese and 20 nonobese individuals, both sexes, mean age ≈49 y; SpainRegional liver and brain iron measured by MRI R2\* relaxationObese individuals had significantly increased regional liver and brain iron load[^13]

RESULTS
=======

Description of the included studies
-----------------------------------

A PRISMA flow chart showing papers included and excluded at each step is shown in ([Figure 1](#nux015-F1){ref-type="fig"}). A total of 2531 potentially relevant articles were identified. After screening titles and abstracts, 129 papers were identified for full-text evaluation. After reviewing, 81 papers were excluded. Of the 48 included papers, 34 described preclinical studies. Nineteen of these focused primarily on behavioral and age-related outcomes ([Table 2](#nux015-T2){ref-type="table"}), and 15 focused on outcomes related to neurodegenerative processes ([Table 3](#nux015-T3){ref-type="table"}). Fourteen studies were conducted in humans: 6 assessed associations between iron nutrition and brain outcomes ([Table 4](#nux015-T4){ref-type="table"}), and 8 assessed associations between peripheral iron status and brain outcomes ([Table 5](#nux015-T5){ref-type="table"}). Figure 1Flow diagram of the literature search process.

Assessment of risk of publication bias
--------------------------------------

After searching meeting abstracts from 9 years of the Society for Neuroscience's database, 5 studies were found that addressed the role of elevated nutritional iron intake in neurodegenerative processes, all in animal models. All 5 abstracts described adverse effects of elevated iron intake on brain outcomes.

Assessment of risk of bias in the included studies
--------------------------------------------------

Assessments of preclinical studies are presented in [Tables 2](#nux015-T2){ref-type="table"} and [3](#nux015-T3){ref-type="table"}. Assessments of clinical studies are presented in [Tables 6](#nux015-T6){ref-type="table"} and [7](#nux015-T7){ref-type="table"}. Table 6Risk-of-bias assessment for human studies assessing associations between iron nutrition and brain outcomesReferenceWas the research question focused?Were appropriate methods used?Was case or cohort recruitment acceptable?Was control recruitment acceptable?Did iron intake estimates minimize bias?Were outcomes measured to minimize bias?Were confounding factors accounted for?Was subject follow-up complete?Are the key results precise?Are the results believable?Anderson et al (1999)[@nux015-B72]NoYesYesYesYesNAYesNANoYesPowers et al (2003)[@nux015-B71]NoYesYesYesYesNAYesNAYesYesPowers et al (2009)[@nux015-B70]NoYesYesYesYesNAYesNAYesYesLogroscino et al (2008)[@nux015-B69]YesYesYesNAYesYesYesYesYesYesHernandez Mdel et al (2015)[@nux015-B68]YesNo[^a^](#tblfn15){ref-type="table-fn"}YesNAYesYesYesYesNoYesHagemeier et al (2015)[@nux015-B67]YesYesYesNAYesYesYesYesYesYes[^14][^15]Table 7Risk-of-bias assessment for human studies assessing associations between peripheral iron status and brain outcomesReferenceWas the research question focused?Were appropriate methods used?Was case or cohort recruitment acceptable?Was control recruitment acceptable?Was iron status estimated to minimize bias?Were outcomes measured to minimize bias?Were confounding factors accounted for?Was subject follow-up complete?Are the key results precise?Are the results believable?Gao et al (2008)[@nux015-B79]YesYesYesNAYesYesYesNAYesYesLam et al (2008)[@nux015-B80]YesYesU[^a^](#tblfn17){ref-type="table-fn"}NAYesYesYesNAYesYesMilward et al (2010)[@nux015-B77]YesU[^b^](#tblfn18){ref-type="table-fn"}YesNAYesYesYesYesYesYesSchiepers et al (2010)[@nux015-B78]YesYesYesNAYesYesYesYesYesYesUmur et al (2011)[@nux015-B75]YesYesYesNAYesYesYesNAYesYesMueller et al (2012)[@nux015-B76]YesYesYesYesYesYesNoYesYesNo[^c^](#tblfn19){ref-type="table-fn"}Andreeva et al (2013)[@nux015-B74]YesU[^b^](#tblfn18){ref-type="table-fn"}YesNAYesYesYesYesYesYesBlasco et al (2014)[@nux015-B73]YesYesYesNAYesYesNoNAYesNo[^d^](#tblfn20){ref-type="table-fn"}[^16][^17][^18][^19][^20]

Preclinical studies of the effect of high iron intake on behavior, brain aging, or neurodegeneration in neonates or adults
--------------------------------------------------------------------------------------------------------------------------

Fifteen studies used a mouse model and 19 a rat model. Five of the studies assessed the effect of elevated iron intake in genetic models of adult-onset neurodegenerative disease,[@nux015-B55]^,^[@nux015-B56]^,^[@nux015-B59]^,^[@nux015-B64]^,^[@nux015-B66] while the remainder studied aging or neurodegenerative processes in wild-type animals. All studies assessed the effect of elevated neonatal iron intake. Levels of daily iron supplementation ranged from 2.5 to 120 mg/kg over a period of 3 to 8 days. All studies except one[@nux015-B45] provided evidence of adverse effects of increased neonatal iron intake on neurologic outcomes. Many of the studies assessed behavioral outcomes only. Sixteen studies evaluated motor outcomes such as open-field and/or rota-rod endurance. Of these, 13 found altered motor behaviors,[@nux015-B41]^,^[@nux015-B46]^,^[@nux015-B52]^,^[@nux015-B60] and 3 did not.[@nux015-B33]^,^[@nux015-B45]^,^[@nux015-B66] Results from memory-based tests such as novel object recognition and/or radial-arm maze were presented in 13 studies.[@nux015-B33]^,^[@nux015-B35]^,^[@nux015-B40]^,^[@nux015-B44]^,^[@nux015-B48]

Brain regional biochemical analyses in the 34 preclinical studies most frequently investigated oxidative stress, neurochemical markers, or iron levels. Markers of brain oxidative stress, including malondialdehyde and protein carbonyls, were increased in 9 studies[@nux015-B34]^,^[@nux015-B49]^,^[@nux015-B55]^,^[@nux015-B63]; the 1 study that assessed glutathione levels found no change.[@nux015-B66] Six studies assessed the effects of neonatal iron intake on brain neurochemistry outcomes. Three of these studies reported decreased striatal dopamine in adult animals,[@nux015-B53]^,^[@nux015-B57]^,^[@nux015-B63] while 2 found no effect on dopamine.[@nux015-B60]^,^[@nux015-B62] One study demonstrated decreased striatal acetylcholinesterase activity,[@nux015-B44] and another found no effect on striatal serotonin.[@nux015-B57] Ten studies reported increased brain iron after neonatal supplementation.[@nux015-B41]^,^[@nux015-B42]^,^[@nux015-B46]^,^[@nux015-B52]^,^[@nux015-B54]^,^[@nux015-B56]^,^[@nux015-B60] Iron levels were elevated in the substantia nigra in 3 of 3 studies, in the basal ganglia in 6 of 7 studies, and in the cerebral cortex in 1 of 8 studies. Two studies found no effect of neonatal iron supplementation on iron levels in the striatum and cortex.[@nux015-B55]^,^[@nux015-B66] Six studies used quantitative pathology to evaluate morphometric changes in the brain; these demonstrated significantly decreased neuronal numbers or neuronal cell body atrophy in specific brain regions.[@nux015-B55]^,^[@nux015-B56]^,^[@nux015-B63] Overall, significant adverse effects of neonatal iron intake on morphologic or biochemical outcomes in specific brain regions were found in the substantia nigra (11 of 11 studies), the basal ganglia (16 of 18 studies), the hippocampus (11 of 12 studies), and the cerebral cortex (6 of 13 studies). Two studies, in addition to assessing the effects of increased iron intake in neonates, also evaluated the effect of elevated iron intake in adult life; no effects in young adult or aged wild-type and Huntington disease mice were found.[@nux015-B55]^,^[@nux015-B66]

Human studies assessing the correlation between iron nutrition or iron status markers and brain outcomes
--------------------------------------------------------------------------------------------------------

Fourteen studies fulfilled the inclusion criteria in assessing the potential correlation between iron nutrition or peripheral markers of iron nutrition and brain-related outcomes. Six studies had the primary purpose of examining the association between estimates of iron intake and brain iron accumulation or risk of Parkinson disease.[@nux015-B67] Of these, 2 cohort studies looked for associations between iron intake and brain iron deposits. One was a large study in the United Kingdom that failed to find a correlation between recent iron intake and magnetic resonance imaging (MRI) measures of brain iron deposition in healthy older individuals.[@nux015-B68] Another smaller study in the United States in middle-aged individuals demonstrated a trend (*P* = 0.075) toward increased MRI-measured brain iron with iron supplementation.[@nux015-B67] Four studies investigated possible associations between iron intake and Parkinson disease.[@nux015-B69] Three of these had a case--control design and recruited study subjects from the state of Washington, USA. The initial smaller study did not find an association between iron intake over most of adult life and the risk of Parkinson disease.[@nux015-B72] Two subsequent larger studies provided some evidence of an association between increased iron intake and risk of Parkinson disease.[@nux015-B70]^,^[@nux015-B71] The fourth study had a cohort design and was very large (94 353 subjects).[@nux015-B69] The authors concluded that increased nonheme iron intake is a risk factor for Parkinson disease, especially when ascorbate deficiency is present.

Eight studies had the primary purpose of determining the presence of associations between peripheral iron status and cognitive or other brain outcomes.[@nux015-B73] Four of these had a cross-sectional design.[@nux015-B73]^,^[@nux015-B75]^,^[@nux015-B79]^,^[@nux015-B80] Three of these reported significant associations of iron levels with brain outcomes.[@nux015-B73]^,^[@nux015-B75]^,^[@nux015-B80] One large study of 1451 older individuals in the United States reported that high plasma iron levels correlated with poorer cognitive outcomes in both men and women.[@nux015-B80]

A much smaller study of 87 nursing home residents in Turkey reported that high serum iron, ferritin, and transferrin saturation were correlated with mild cognitive impairment.[@nux015-B75] Another small Spanish study of 23 obese and 20 nonobese middle-aged individuals found that MRI-measured brain and liver iron was elevated in obese individuals.[@nux015-B73] One study of 2000 elderly individuals from rural areas of China reported no correlation between plasma iron and cognitive scores.[@nux015-B79] Three studies used a cohort design.[@nux015-B74]^,^[@nux015-B77]^,^[@nux015-B78] A study of 800 older adults in Australia found no correlation between serum iron, transferrin saturation, or ferritin levels and cognitive outcomes.[@nux015-B77] One French study of 4959 middle-aged individuals reported associations between lower serum ferritin and better cognitive outcomes, but only in pre- and perimenopausal women.[@nux015-B74] A Netherlands-based study of 818 middle-aged and older individuals found no evidence of an association between peripheral measures of iron and cognitive performance.[@nux015-B78] Finally, a case--control study of 37 older individuals in the United States found that serum nonheme iron did not increase during the progression from mild cognitive impairment to Alzheimer disease.[@nux015-B76]

DISCUSSION
==========

This systematic review examined evidence from animal and human studies that investigated whether high iron intake or markers of iron status correlated with cognitive decline or the onset/progression of neurodegenerative disease. Almost all the animal studies assessed the effects of elevated iron intake in neonatal life on outcomes in early to late adult life. These studies overwhelmingly demonstrated adverse effects of high neonatal iron intake on diverse behavioral, brain morphologic, and biochemical outcomes. In striking contrast, none of the human studies assessed the effects of high iron intake in early life on adult cognitive or brain iron outcomes.

There is substantial evidence that early-life environmental factors, including nutrition, influence brain development, which may then impact susceptibility to brain aging or neurodegenerative processes in later life.[@nux015-B81] Since brain iron accumulation is linked to aging and neurodegenerative processes, it is important to understand the effects of high iron intake at various life stages on the human brain. Preclinical studies evaluated the effects of neonatal iron intake on outcomes related to behavior and aging processes ([Table 2](#nux015-T2){ref-type="table"}) and on neurodegenerative processes in wild-type and genetically modified animals ([Table 3](#nux015-T3){ref-type="table"}). None of the studies fulfilled all the methodological criteria for quality. Although the strength of many studies was weakened by underreporting of methodological details, all but 1 preclinical study[@nux015-B45] ([Table 2](#nux015-T2){ref-type="table"}) provided evidence that elevated iron intake in early life adversely affects cognition in adult rodents. Although outcomes in early adult life were studied most frequently, iron supplementation did increase brain regional iron levels, a marker of brain aging.[@nux015-B15]^,^[@nux015-B16] Studies focused on neurodegenerative disease outcomes ([Table 3](#nux015-T3){ref-type="table"}) also provide evidence that neonatal iron supplementation promotes age-dependent progressive neurodegeneration in the substantia nigra, the main area of brain degeneration in Parkinson disease.[@nux015-B53]^,^[@nux015-B57]^,^[@nux015-B63] Preclinical studies investigating interactions between neonatal iron nutrition and gene mutations causing neurodegeneration showed evidence of synergism between iron intake and genetic disease factors, although the number of studies was small.[@nux015-B55]^,^[@nux015-B64]^,^[@nux015-B66] These findings suggest that individuals with gene mutations causing protein-misfolding neurodegenerative diseases may have increased susceptibility to the adverse effects of high iron intake in early life.

Exactly how the effects of neonatal iron intake in mice translate to humans is unclear. The form and the dose of iron supplementation are key factors affecting the interpretation of preclinical studies. Soluble ferrous succinate and insoluble iron carbonyl were used in the included preclinical studies; both forms are used for human supplementation. There was considerable variation in the daily dose of iron used in the neonatal iron supplementation studies. The highest dose of 120 mg/kg was used only with iron carbonyl, which has less bioavailability than ferrous salts.[@nux015-B82] This highest level of supplementation in mice is estimated to result in an approximate 40-fold increase over the iron present in natural milk. Human infants fed iron-fortified formula have an iron intake level of up to 14 mg/d, which is also about 40-fold the intake level of breastfed infants.[@nux015-B41]^,^[@nux015-B63]^,^[@nux015-B83] Therefore, when translating iron dose on a milligram-per-kilogram (mg/kg) basis from rodents to humans, the highest levels of supplementation used in the preclinical studies appear relevant to human nutrition.

All of the included human studies assessed the effect of adult-life iron intake or iron status on brain outcomes. These studies varied considerably in design, size, and outcomes measures. Study qualities were generally good ([Tables 6](#nux015-T6){ref-type="table"} and [7](#nux015-T7){ref-type="table"}). However, not surprisingly, results varied widely ([Tables 4](#nux015-T4){ref-type="table"} and [5](#nux015-T5){ref-type="table"}). Several of the human studies used Parkinson disease as their outcome, which is not surprising, given the evidence of an association between substantia nigra iron accumulation and Parkinson disease.[@nux015-B86] The most complete iron nutrition study, based on the large number of subjects, the prospective study design, and the repeated food questionnaire analysis performed every 4 years, was that of Logroscino et al.[@nux015-B69] ([Table 4](#nux015-T4){ref-type="table"}). These authors concluded that increased nonheme iron intake is a risk for Parkinson disease, especially when concurrent ascorbate deficiency is present. The literature searches conducted for the present review, however, did not identify any preclinical studies evaluating the effect of high iron intake in adult life on Parkinson disease outcomes in animal models. Preclinical studies that use varied outcomes would inform the need for additional human adult iron-nutrition studies assessing the risk for Parkinson disease development. Most studies evaluating the effects of peripheral iron status found evidence to support an association with poorer outcomes ([Table 5](#nux015-T5){ref-type="table"}). A weakness of the studies investigating blood iron status is that comprehensive measures of peripheral iron status were frequently not used. Furthermore, although some studies accounted for confounding factors, many did not account for the presence of inflammatory disease, which influences iron status.[@nux015-B87]^,^[@nux015-B88]

CONCLUSION
==========

When the results of animal studies are combined, there is moderately strong evidence that nutritionally relevant levels of high iron intake during early postnatal life have adverse effects on the adult brain. Future preclinical studies could focus on improving the understanding of how high neonatal iron intake impacts the brain in adult life. Thus far, human studies of the effects of high iron intake on cognition and risk of disease do not strengthen these preclinical findings because they have investigated the effects of iron intake only in adult life. There are significant challenges, such as cost and time, when conducting prospective studies to examine the effects of early-life high iron intake on adult cognition and brain aging processes. Retrospective studies are also challenging because of the potential for recall bias. Nevertheless, the need for human studies in this area is supported by the preclinical findings reported in the literature. Human studies should assess factors besides nutrition that influence iron status, such as physiologic blood loss, gene polymorphisms, and the presence of inflammatory disease processes to better determine the role of iron nutrition on the outcomes investigated.
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[^1]: *Abbreviations*: H, high risk of bias; L, low risk of bias; U, unclear risk of bias.

[^2]: ^a^Iron was delivered by gavage.

[^3]: ^b^Left to right: random allocation of treatment, concealment of allocation, blinding, inclusion/exclusion criteria, test animal details, every animal accounted for, and conflicts of interest and funding sources reported.

[^4]: ^c^Only funding information was reported.

[^5]: ^d^Only behavioral studies were blinded.

[^6]: *Abbreviations*: AD, Alzheimer disease; H, high risk of bias; HD, Huntington disease; L, low risk of bias; L-DOPA, L-3,4-dihydroxyphenylalanine; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; PD, Parkinson disease; U, unclear risk of bias.

[^7]: ^a^Iron was delivered by gavage to neonates and in feed to adults.

[^8]: ^b^Left to right: random allocation of treatment, concealment of allocation, blinding, inclusion/exclusion criteria, test animal details, every animal accounted for, and conflicts of interest and funding sources reported.

[^9]: ^c^Only funding information was reported.

[^10]: ^d^Whole litters were randomized to receive iron supplementation.

[^11]: ^e^Only histopathology studies were blinded.

[^12]: *Abbreviations*: FFQ, food frequency questionnaire; MRI, magnetic resonance imaging; OR, odds ratio; PD, Parkinson disease.

[^13]: *Abbreviations*: CI, cognitive impairment; MRI, magnetic resonance imaging.

[^14]: *Abbreviation*: NA, not applicable for study.

[^15]: ^a^The timing and the period of dietary intake analysis were not optimal. Unclear inclusion and exclusion criteria.

[^16]: *Abbreviations*: NA, not applicable for study; U, unclear inclusion and exclusion criteria.

[^17]: ^a^Inclusion and exclusion criteria unclear.

[^18]: ^b^Lack of controls to measure cognition at baseline.

[^19]: ^c^Small group sizes (n = 18--19).

[^20]: ^d^Small group sizes (n = 20--23).
